


 Cite this: *RSC Adv.*, 2019, **9**, 19571

 Received 22nd April 2019
 Accepted 17th June 2019

 DOI: 10.1039/c9ra02985k
rsc.li/rsc-advances

Next-generation of selective histone deacetylase inhibitors

 Feifei Yang, ^{ab} Na Zhao,^a Di Ge^a and Yihua Chen, ^{*b}

Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of cancers. First-generation inhibitors are mainly pan-HDACis that target multiple isoforms which might lead to serious side effects. At present, the next-generation HDACis are mainly focused on being class- or isoform-selective which can provide improved risk–benefit profiles compared to non-selective inhibitors. Because of the rapid development in next-generation HDACis, it is necessary to have an updated and state-of-the-art overview. Here, we summarize the strategies and achievements of the selective HDACis.

1. Introduction

Epigenetic regulations have been considered to be one of the important factors in tumor initiation and progression,¹ among which acetylation is one of the most well studied modifications.² The acetylation status is controlled by two counteracting enzyme families: the histone acetyltransferases (HATs) and the histone deacetylases (HDACs).³ Both of these enzymes exert their actions on the ε-amino group of Lys residues.^{4,5} Acetylation of the lysine side chains is linked to transcriptionally active genes, while hypoacetylated histones are associated with transcriptionally silent regions of the genomes.^{6–8} To date, 18 human HDACs were identified and classified into four classes according to their sequence homologies to yeast and domain organization: class I (HDACs 1, 2, 3 and 8), class II (HDACs 4, 5, 7, 9, 6 and 10), class III (SIRT1–7), and class IV containing a single isoform (HDAC11).^{9,10} As shown in Table 1. Class I, class II and class IV HDACs are Zn²⁺-dependent enzymes, whereas class III HDACs are structurally distinct and are characterized by their nicotinamide adenine dinucleotide (NAD⁺) dependency.^{11,12}

Class I HDACs include HDACs 1, 2, 3 and 8, which are primarily located in the nucleus and homologous to the yeast RPD3 protein,²⁶ which are expressed ubiquitously in various human tissues and generally play an important role in cell proliferation, differentiation and cell cycle progression *etc.*²⁷ A prominent feature of class I HDACs, with the exception of HDAC8, is that their functions are mediated as part of multi-protein complexes. These cofactors are necessary for their deacetylases activities and modulating the interactions of other

cooperative HDACs with the promoters of genes.²⁸ HDAC1 and HDAC2 interact with each other to form the catalytic core of several large complexes such as CoREST, NuRD and Sin3A complexes.^{29–31} It is essential to point out that HDAC1 and 2 are usually co-expressed and the homo and/or heterodimers are essential for their catalytic activities. HDAC3 is generally found in complex with HDAC4, 5 and 7 or the nuclear receptor corepressors (N-CoR) and SMRT.^{32,33} HDAC8, differing from the other class I HDACs, is mainly restricted in specific tissue and displays deacetylase activity as a single polypeptide (Fig. 1).^{34,35}

Class II HDACs (HDACs 4, 5, 6, 7, 9 and 10) are homologous to the yeast Hda1 protein, and have both histone and non-histone proteins targets.³⁶ This class HDACs can be further classified in two subclasses based on the presence or absence of a double catalytic domain. Class IIa includes HDACs 4, 5, 7 and 9 and class IIb includes HDACs 6 and 10.³⁷ Class IIa HDACs show poor deacetylase activities unless acting in concert with class I HDACs.^{38,39} For example, the catalytic domain of HDAC4 is interacted with HDAC3 within a larger NCoR-SMRT complex, and HDAC4 is essential for HDAC activity and transcriptional repression of target genes by the NCoR-SMRT-HDAC3 complex.^{40,41} HDAC6 is a unique histone deacetylase: it features two independent catalytic domains and which can deacetylate α-tubulin *in vitro* and *in vivo*.^{42,43} Through the deacetylation of tubulin, HDAC6 plays a central role in cytoskeleton regulation and cytoskeleton mediated processes, such as cell–cell interaction and cell migration.⁴⁴

2. Histone deacetylase inhibitors (HDACis)

HDACs play a pivotal role in the regulation of multiple processes of life, from gene expressions to protein activities. Importantly, the high expression of HDACs were found in several types of cancers.^{45,46} For instance, transcriptional

^aSchool of Biological Science and Technology, University of Jinan, Jinan, Shandong Province 250022, China

^bShanghai Key Laboratory of Regulatory Biology, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China.
 E-mail: yhchen@bio.ecnu.edu.cn



Table 1 Classification of histone deacetylases (HDACs) enzymes^a

| Class | Member | PDB code | Location | Expression |
|---|--------|--------------------|-------------------|------------|
| Class I (Zn ²⁺ -dependent) | HDAC1 | 4BKX ¹³ | Nucleus | Ubiquitous |
| | HDAC2 | 4LXZ ¹⁴ | | |
| | HDAC3 | 4A69 ¹⁵ | | |
| | HDAC8 | 1T64 ¹⁶ | | |
| Class IIa (Zn ²⁺ -dependent) | HDAC4 | 2VQM ¹⁷ | Nucleus/cytoplasm | Specific |
| | HDAC5 | — | | |
| | HDAC7 | 3C10 ¹⁸ | | |
| | HDAC9 | — | | |
| Class IIb (Zn ²⁺ -dependent) | HDAC6 | 5EDU ¹⁹ | Mainly cytoplasm | Specific |
| | HDAC10 | — | | |
| Class III (NAD ⁺ -dependent) | SIRT1 | 4ZZH ²⁰ | Nucleus | Ubiquitous |
| | SIRT2 | 1J8F ²¹ | Cytoplasm | |
| | SIRT3 | 3GLS ²² | Mitochondria | |
| | SIRT4 | — | Mitochondria | |
| | SIRT5 | 3RIG ²³ | Mitochondria | |
| | SIRT6 | 3K35 ²⁴ | Nucleus | |
| | SIRT7 | 5IQZ ²⁵ | Nucleus | |
| Class IV (Zn ²⁺ -dependent) | HDAC11 | — | Nucleus/cytoplasm | Ubiquitous |

^a “—” This type *Homo sapiens* HDAC isoform don't display PDB code.

upregulation of HDAC1 is observed in colorectal and pancreatic cancers. In addition, HDAC3 in lung and colon cancers, HDAC8 in neuroblastoma were also found to be overexpressed.^{47–49} HDACs not only can remove the acetyl group from the histones but also deacetylate other non-histone proteins pertaining to the origin and development of tumors.^{50–53} In tumors, the biological functions of HDACs are mainly involved in the promotion of the proliferation, invasion, migration and angiogenesis of tumor cells.^{54,55} Therefore, HDACs are proposed to have great potentials in the therapies of human cancers.⁵⁶

Most HDACs share the common pharmacophore models which consist of three parts: a cap part, a zinc binding group (ZBG), and a linker part connecting ZBG and cap part (Fig. 2).^{57,58} The cap group usually has an aromatic character or heteroaromatic hydrophobic moiety which mediates the interaction with the amino acids at the rim of the enzyme,⁵⁹ and which is mainly responsible for the HDAC isoforms selectivities.⁶⁰ ZBG acts as the chelating one for Zn²⁺ in the active site of HDACs, modification of the ZBG can introduce a change in potency of inhibitors.⁶¹

The first X-ray structure of histone deacetylase like protein (HDLP) with TSA was elucidated by Finnin *et al.* in 1999 (Fig. 2A and B).⁶² The structure revealed the presence of a tube-like, 11 Å internal channel for accommodation of the inhibitor. The hydroxamic acid is bound to the active site Zn²⁺ center, present at the bottom of the internal channel. Another 14 Å internal cavity, is adjacent to the active site. Crystal structure of HDAC8 with SAHA was shown in Fig. 2C, and the binding mode was similar to TSA with HDLP. Fig. 2D displayed the binding interaction of SAHA at active site of HDAC8, the hydroxamic

acid group of SAHA makes the same contacts to the Zn²⁺ and active-site residues.⁶³

Based on ZBG chemical structures, HDACs could be divided into five main classes: hydroxamates, cyclic peptides, benzamides, short-chain fatty acids, ketones and others.^{64,65} Among which, HDACs containing hydroxamates are the most investigated and potent.⁶⁶ However, most hydroxamates are pan-HDACs, while the benzamides have increased class I selectivities. Until now, four HDACs, namely Vorinostat (1, SAHA), Belinostat (2, PXD101), Panobinostat (3, LBH589), Romidepsin (4, FK228) have been approved by the US FDA and one HDACi, namely Chidamide (5, CS005) was approved by the China FDA, for the treatments of hematologic malignancies and more than 20 inhibitors are now in clinical trials^{67–71} (Fig. 3).

3. Selective HDACs

The current HDACs are mostly belong to pan-inhibitors with several obvious side effects, such as fatigue, thrombo-cytopenia and gastrointestinal.^{72,73} Considering the distinct tissue distribution and cellular localization of individual HDACs, as well as




Fig. 2 The common pharmacophore model of HDACs. (A) Space-filling representation of TSA in the active-site pocket of HDLP. (B) Schematic representation of HDLP-TSA interactions (adapted with permission from ⁶²). (C) Crystal structure of HDAC8 with SAHA. (D) Binding mode of SAHA with HDAC8 (this figure was cited from ref. 63).




Fig. 1 Representative class I HDAC complexes.²⁸






Fig. 3 Examples of HDACis with different ZBG types.

the relationship between specific HDAC isoforms and different kinds of cancers, researchers hypothesized isoform-selective HDACis may possess better therapeutic index and fewer adverse effects.^{74–76} However, the therapeutic advantages of isoform-selective HDACis have not yet been proved clinically, and are still in course of studies.^{77,78}

3.1. Class I selective HDACis

Crystal structures of the catalytic domain of all class I HDACs have been solved by X-ray diffraction. There is only one residue difference between HDAC 1 and 2, S263 in HDAC1 and A264 in HDAC2. In HDAC3, there is one insertion of phenylalanine (F199), which alters the orientation of tyrosine (Y198). The most noticeable difference in HDAC8 is loop L1, formed by seven amino acid residues (residues 30–36) (Fig. 4A).⁷⁹ The flexible L1 loop is required for selective inhibitors binding to a HDAC8-specific pocket which is absent in other class I HDACs (Fig. 4B and C).⁸⁰

3.1.1. Inhibitors of HDAC1-3. Many class I HDAC inhibitors contain 2-aminoanilide as ZBG, such as 12 (MS-275) and 13 (MGCD0103), which were selective for HDAC1-3.²⁸ This type of inhibitors exploited a foot pocket close to the active site, which was only exist in HDAC1-3. Compound 12 and 13 displayed IC₅₀ values in the nM range against HDAC1 and HDAC1&2, respectively.^{81,82} Compound 14 with bulky branched cap group displayed 10-fold and 20-fold potencies for HDAC1 compared to HDAC2 and HDAC3, respectively.⁸³ Crystal structure of HDAC2 with 2-aminoanilide scaffold confirmed that the anilide scaffold could access the foot pocket next to the catalytic region. Then several 2-aminoanilides substituted in 5-position were designed for further occupying this foot pocket. Compound 15 displayed




Fig. 4 (A) Class I HDAC crystal structures (this figure was cited from ref. 79). (B) Surface representation of the pocket accommodating the linker and capping groups of the HDAC8-selective inhibitors. (C) Surface representation of the same region in hHDAC3 (this figure was cited from ref. 80).

a 5-fold selectivity for HDAC1 over HDAC2.⁸⁴ Compound 16 has been synthesized for the specific inhibition of HDAC1 and 2 *versus* HDACs 3–8 and compound 17 displayed high selectivity for HDAC1, with a 31-fold increase compared to HDAC2 (Fig. 5).⁸⁵

Based on a series of 504 triazole candidates, Suzuki *et al.* designed a series of HDAC3 selective inhibitors and found compound 18 showed potent HDAC3 inhibition with sub-micromolar IC₅₀, and which didn't inhibit other HDAC isozymes even at 100 μ M.⁸⁶ Marson *et al.* described an oxazoline capping group with a *N*-(2-aminophenyl) benzamide unit, and compound 19 displayed good inhibitory activity against HDAC3, almost a 13-fold increase compared to HDAC1.⁸⁷ Hsieh *et al.* developed a series of HDAC3 selective inhibitors, the target compounds 19A and 19B displayed high HDAC3 potency and selectivity. Especially, they exhibited efficacy in suppressing TNBC cells *via* the downregulation of β -catenin. Furthermore, compound 19B suppressed tumorigenesis *in vivo* (Fig. 6).⁸⁸

3.1.2. Inhibitors of HDAC8. HDAC8 is a HDAC isoform containing 377 amino acids residues with stand-alone deacetylase activity *in vitro* that can localize in either the nucleus or




Fig. 5 Structures of some benzamides selective inhibitors.






Fig. 6 Structures of some benzamides selective inhibitors.

the cytoplasm.⁸⁹ The L1 loop, formed by seven amino acids residues (Ser30, Leu31, Ala32, Lys33, Ile34, Pro35 and Lys36), is highly flexible, which is located toward the proximity of the active site and can undergo conformational changes for substrates binding. The Ser39 phosphorylation near the catalytic site is special for HDAC8,¹⁶ which will attribute to design specific HDAC8 inhibitors.

Compound 20 (PCI34051, Fig. 7.) was probably the most widely used HDAC8 specific inhibitor, reported by Balasubramanian *et al.* This hydroxamic acid possessed potent HDAC8 inhibition with an IC_{50} of 10 nM and was >200 fold selectivity over HDACs 1/2/3/6/10. The 4-methoxybenzyl fits into the sub-pocket of HDAC8 which may be a reason for the selectivity toward HDAC8 enzyme.⁹⁰

Zhang *et al.* reported a series of tetrahydroisoquinoline-based hydroxamic acid HDAC8s.⁹¹ The tertiary butyloxycarbonyl (Boc) group was located on the secondary amine atom and 4-methoxy-phenyl group seemed beneficial to HDAC8 inhibitory activity. Molecular docking study displayed that the methoxyphenyl group could form π - π interaction with Tyrosine 100 (Y100). Zhang *et al.* further optimized the lead compound 21,⁹² compounds with Boc group were shown more potent activities than their corresponding deprotected analogues which indicated that the hydrophobicity of the cap group is very beneficial to the inhibitory activities. Based on the compound 21a, more potent compounds were synthesized. However, further cellular activities evaluations revealed that their




Fig. 7 Chemical structure of compound 20 (PCI34051) and the docking pose of PCI34051 in the side pocket of HDAC8 (PDB ID 2VX5) (this figure was cited from ref. 90).

antiproliferative activities were not as excellent as its HDACs inhibitory activities. Among these compounds, compound 22 showed the highest HDAC8 inhibitory activity (IC_{50} = 47 nM), about 2-fold selective over HeLa nuclear extract (HDAC1 and 2) and 4-fold selective over HDAC6 (Fig. 8).

Zhang *et al.* also designed and synthesized a series of tripeptidomimetics HDAC8s with spiro-ring containing sulfur atoms as a cap group, several compounds showed outstanding potencies against HDAC8.⁹³ The results revealed that branched cap groups with aromatic ring could efficiently increase its inhibitory activities. In brief, a hydrophobic Boc-protected amino group was optimal for HDAC8 inhibitory activity compared with the Boc-cleaved counterpart. Compound 24a (IC_{50} = 35 nM) and compound 24b (IC_{50} = 21 nM) were 28- and 21-fold HDAC8 selective over HDAC1, respectively. In the following work, Zhang *et al.* developed a novel series of *N*-hydroxy-3-sulfamoylbenzamide-based HDAC8 selective inhibitors. Three compounds 25a-c showed effective HDAC8 inhibition with nanomolar IC_{50} values, and possessed selective anti-proliferative activities to two T-cell leukemia cell lines (Fig. 9).⁹⁴

Neelarapu *et al.* described potent isoxazole- and pyrazole-based HDAC3 and HDAC8 diazide probes.⁹⁵ The bulky substituent in the *para* position of the terminal phenyl ring of target compounds leads to its lower activities for HDAC8 and compounds with the azide group exhibited tolerable HDAC8 inhibitory activities. The most potent compound 26 was 8-fold more active toward HDAC8 than for HDAC3. Docking studies suggested that the pyrazole-based ligands are flexible enough to occupy the second binding site of HDAC8 (Fig. 10).

Tang *et al.* developed an efficient synthetic method in 96-well plates for high throughput screening selective HDAC8 inhibitors.⁹⁶ It could be found that compounds with comparatively bulky heteroaryl cap group as well as the aromatic linker displayed better HDAC8 inhibitory activities. Compound 29 possessed the best HDAC8 inhibition (IC_{50} = 23 nM) among the investigated ones (Fig. 11).

Suzuki *et al.* designed a library of triazole-containing HDAC8 inhibitors using click chemistry-based Cu(i)-catalyzed-azide-alkyne cycloaddition (CuAAC).⁹⁷ Compound 30, the most active HDAC8 selective inhibitor in this series, had a U-shaped conformation in the active site of HDAC8, especially, the phenylthiomethyl group binds to a hydrophobic pocket formed by Trp141, Ile34, and Pro35, which is unique to HDAC8. The triazole ring is also important to fix the orientation of the hydroxamate and the phenylthiomethyl group appropriately, which is mainly responsible for HDAC8 inhibitory activity and selectivity. In order to further optimizing the triazole linker motif, a new series of compounds were synthesized, in which the triazole ring of 30 (NCC149) was changed with phenyl or various five-membered aromatic rings.⁹⁸ The results demonstrated that the five-membered ring is still necessary for fixing the orientation of hydroxamate and the hydrophobic pocket-binding phenylthiomethyl group. Compound 31, with reversed triazole, showed more potent HDAC8 inhibitory activity than 30 (Fig. 12).

Ingham *et al.* discovered a highly potent HDAC8 inhibitor with IC_{50} = 0.8 nM.⁹⁹ From the SAR study, it was observed that






Fig. 8 Structures of tetrahydroisoquinoline-based HDAC8 inhibitors.




Fig. 9 Structures of novel HDAC8 inhibitors.




Fig. 10 Structures of pyrazole-based HDAC8 inhibitors.




Fig. 11 Structures of heteroaryl-based HDAC8 inhibitors.

small hydrophobic groups at the R₃ position, such as cyclopropane (32), were found to be beneficial and afforded greater inhibitions. At the same time, reduction of the alkyne resulted in the loss of inhibitory activity (Fig. 13).

Huang *et al.* developed an *ortho*-aryl N-hydroxycinnamide HDAC8 inhibitors *via* structure-based drug design strategy (SBDD) and molecular modeling techniques.¹⁰⁰ The results displayed that *ortho*-aryl substituted compounds showed higher potency than corresponding *para* substituted analogues, the *ortho*-oriented benzyl group may occupy the secondary hydrophobic surface pocket of HDAC8, thereby contributing to HDAC8 selectivity of compound 33. The molecular docking analysis showed that further hydrophobic incorporation into the *ortho*-phenyl moiety may make additional interactions to the active site of HDAC8, then more potent and more selective HDAC8 inhibitor (compound 34) was acquired, two to three-fold more potent than 33. In addition, compound 34 showed higher cytotoxicity against than 20 in three cancer cell lines (Fig. 14).

Taha *et al.* described the design and synthesis of a novel series of C1-substituted tetrahydroisoquinoline (TIQ)-based HDAC8 inhibitors.¹⁰¹ The TIQ-based compounds 35 and 36 displayed the highest potencies with IC₅₀ values of 82 and 55 nM against HDAC8 and 330- and 135-fold selectivities over HDAC1, respectively. Docking studies showed that the C1-substituent pointed into the HDAC8 extended pocket (Fig. 15).

3.2. Class II selective HDACis

3.2.1. Inhibitors of HDAC6. The surface area of HDAC6 are different in shape and the channel of HDAC6 appears shallower and wider than other HDAC isoforms, which makes it possible for development of HDAC6 selective inhibitors.¹⁰² HDAC6, as the only HDAC containing two catalytic domains (Fig. 16A), is mainly expressed in the cytoplasm.^{103,104} The first catalytic domain (CD1) is enzymatically active. However, the second catalytic domain (CD2) is mainly responsible for the




Fig. 12 Structures of triazole-based HDAC8 inhibitors.




Fig. 13 Structures of triazole-based HDAC8 inhibitors.




Fig. 14 Structures of *ortho*-aryl *N*-hydroxycinnamide-based HDAC inhibitors.

Fig. 15 Structures of tetrahydroisoquinoline-based HDAC8 inhibitors.

deacetylation of non-histones, such as α -tubulin, Hsp90 and cortactin,¹⁰⁵ therefore HDAC6 plays a substantial role in chaperone activities and microtubule dynamics, which are responsible for cell mobility.^{106,107} Indeed, up-regulated expression of HDAC6 has been found closely linked to the invasive metastatic behavior of cancer cells.¹⁰⁸ Therefore, HDAC6 represents a potential target for further investigation considering its therapeutic applications.

Crystal structures of CD2 complexed with broad-specificity inhibitors and HDAC6-selective inhibitor HPOB revealed that the cap group of broad-specificity inhibitors clustered around a 'hotspot' on the L1 loop, and the hydroxamate hydroxy and carbonyl groups were interacted with H573 and Y745. However, only the hydroxy of hydroxamate group of HPOB coordinated to Zn^{2+} (Fig. 16B–D).¹⁹ These data suggested that HDACis with bulky and short aromatic linker, big, rigid and hydrophobic cap are more efficient to achieve HDAC6 selectivity, which could preclude a closer approach of the hydroxamate group to Zn^{2+} , and prevent the cap group of HDAC6 selective inhibitors from interacting with the L1 loop.¹⁰⁹

Fig. 16 (A) HDAC6 harbors a unique substrate-binding site (this figure was cited from ref. 104). (B) Superposition of broad-specificity HDACis (thin wheat stick figures) and the HDAC6 selective inhibitor HPOB (thin orange stick figure). (C) Close-up view of the Zn^{2+} binding site in the hCD2 complexes with broad-specificity HDACis. (D) Close-up view of the Zn^{2+} binding site in the hCD2-HPOB complex (this figure was cited from ref. 19).

Compound 37 (Tubacin), the first reported HDAC6 inhibitor, was developed by Schreiber and co-workers through cell-based screening of 7392 compounds.¹¹⁰ Tubacin was a "T" type structure with unique surface recognition region, including five aromatic rings and a dioxane scaffold. Studies have indicated that Tubacin showed different effects on HDAC1, HDAC6 and HDAC8, which were mainly derived from the surface difference between class I and class II HDACs.¹¹¹ Unfortunately, its high lipophilicity made it more useful as a chemical tool other than a drug candidate. Compound 38 (ACY-1215) was the first HDAC6 selective inhibitors in clinical studies. Low doses of 38 combined with bortezomib or lenalidomide in anti-multiple myeloma can produce synergistic therapeutic effects.¹¹² The structurally related drug ACY-241 was another selective HDAC6 inhibitor in phase I clinical development (Fig. 17).¹¹³

Kozikowski *et al.* prepared a series of biphenyl and phenylthiazole hydroxamic acid HDAC6 inhibitors.¹¹⁴ The phenylthiazole HDACi 40 was more potent than the biphenyl compound 39. Also, introduction of a Boc group led to an enhancement in the inhibitory activity toward HDAC6. However, the more HDAC6 selective analogues displayed




Fig. 17 Structures of novel HDAC6 inhibitors.






Fig. 18 Structures of heteroaryl-based HDAC6 inhibitors.

reduced potencies against a panel of pancreatic cancer cell lines, which suggested that the anticancer properties of these compounds may not due to HDAC6 inhibition but with off-target effects. The same research group further developed a set of triazolylphenyl-based HDACi with modification at the cap region,¹¹⁵ the results showed that the substitution pattern of the central phenyl ring played a significant role in the selectivity for inhibition of HDAC6 over HDAC1. Using of nitrile oxide cycloaddition (NOC) chemistry, Kozikowski and co-workers reported potent HDACis which contained the aryl substituted isoxazole cap.¹¹⁶ Compound 43 displayed an impressive potency of 2 pM against HDAC6 together with a superb level of enzyme selectivity. The cap region interacted with only one side of the HDAC6 enzyme. The carbonyl group of the Boc group could interact with His499, which may be important in positioning the cap residue on the surface of protein (Fig. 18).

Based on molecular docking study and the feasibility analysis of synthesis, Yang *et al.* designed novel selective HDAC6 inhibitors using the quinazoline as the cap region.¹¹⁷ The SAR analysis indicated that the hydroxamic acid side chain on C-3 and introduction of a methoxy group to the C-4 position was necessary to keep the activity and selectivity on HDAC6. Compound 44, was the most potent selective inhibitor in these series of compounds for HDAC6 with an IC₅₀ value of 17 nM and showed 25-fold and 200-fold selectivities relative to HDAC1 and HDAC8, respectively. This compound also displayed excellent low nanomolar antiproliferative effects against both the hematological and solid cancer cells (Fig. 19).

On the basis of the strategy for creating multifunctional drugs, Duan *et al.* reported a novel series of phenylsulfonyl-furoxan-based hydroxamates with HDAC inhibitory and NO donating activities.¹¹⁸ The most potent hybrid, 45, displayed potent HDAC6 activity with IC₅₀ of 7.4 nM, however, it exhibited pan-HDAC inhibition in a Western blot assay, which was likely




Fig. 19 Structures of quinazoline-based HDAC6 inhibitors.

due to class I HDACs inhibition caused by NO release at the cellular level. Further studies revealed that this compound induced a much stronger apoptotic effect and G1 phase arrest in HeLa cells as well as exhibited greater oral antitumor potency than SAHA *in vivo* (Fig. 20).

Based on celecoxib, Yang *et al.* designed and synthesized a series of HDACis bearing phenylpyrazol moiety.¹¹⁹ SAR analysis indicated that locating the linker group at 1' of pyrazole gave the most selectivity, the most selective HDAC6 inhibitor 46, was with IC₅₀ value of 20 nM. Docking studies revealed that compound 46 could occupy the hydrophobic pocket of HDAC6 with a π-π stack between phenyl ring and Phe679, which could account for the selectivity of 46 against HDAC6.

Yang *et al.* described a pharmacophore combining the pacritinib and vorinostat with JAK2 and HDAC bispecific inhibitors.¹²⁰ Compound 47, with single-digit nanomolar potencies against JAK2 and HDAC6, showed broad anti-proliferative potencies across a range of solid and hematological cell lines. Based on Ruxolitinib and Vorinostat, this group developed a new series of pyrazole substituted pyrrolopyrimidine based hydroxamates with HDAC and JAK inhibitory activities.¹²¹ Finally, compound 48 with the optimal length of six carbons and methyl group, displayed single digit nanomolar potency against HDAC6. On this basis, Yao *et al.* explored alternative attachment points for the hydroxamate bearing chain and the pyrazole substituent.¹²² When the pyrazole was substituted with homoallyl, compound 49, had a sub-nanomolar IC₅₀ against HDAC6 of 0.25 nM and selectivity over HDAC1 with more than 300-fold potency. Binding models displayed that the homoallyl pyrazole substituent occupied in a shallow hydrophobic pocket around Thr678 and Met682 which could explain the observed strong inhibition of HDAC6 (Fig. 21).

Butler *et al.* found that the active channel of HDAC6 is wider and shallower than HDAC1 (17.5 Å vs. 12.5 Å), thus replacement of the traditional long methylene linker with bulkier and shorter aromatic moieties may help to enhance the selectivity for HDAC6.¹²³ Then a series of carbazole based hydroxamic acids with alkylaryl linker were synthesized. However, as the carbazoles are too lipophilic, a tertiary amine was introduced to the tricyclic ring. The tetrahydro-γ-carboline analogue, compound 50 (Tubastatin A), with an IC₅₀ of 15 nM against HDAC6 and over 1000-fold selectivity against HDAC1. In order to investigate a second generation of these compounds, a series of substituted β- and γ-carbolines based hydroxamic acids were designed,¹²⁴ the subsequent SAR analysis found that substitutions to the 6-, 7-, 8-, and 9-positions of the cap group were not




Fig. 20 Structures of novel HDAC6 inhibitors.




Fig. 21 Structures of pyrrolopyrimidine based HDAC6 inhibitors.

beneficial to increasing the selectivities of these compounds, while introducing aromatic functionalities at the 2-position were beneficial. Compound **51**, with a 4-pyridyl group, showed subnanomolar potency against HDAC6 as well as approximately 5000-fold selectivity over HDAC1. By using a bicyclic cap as the structural scaffold, Shen *et al.* developed a set of benzimidazole based inhibitors that showed comparable potency and selectivity against HDAC6.¹²⁵ Especially, compound **52**, with a fluorine atom at the 3-position of the aryl linker, led to the increased lipophilicity, which may improve binding energies correlating with improved HDAC6 inhibition. Modeling studies revealed that benzimidazole could stabilize π - π stacking with Phe680 and the methyl group fitted into a small sub-pocket that aided in cap region of HDAC6. At the same time, this compound possessed improved pharmacokinetic properties compared to Tubastatin A. Lee *et al.* developed a series of 5-aryloylindolyl substituted hydroxamic acids HDAC6 inhibitors for Alzheimer's disease. The most potent compound **53**, with an IC₅₀ value of 3.92 nM, was able to reduce tau phosphorylation and aggregation. The docking studies showed that the cap region of compound bound to the specific pocket of HDAC6 and the anisole moiety could form van der Waals interactions with residues N494, D496, and W497 (Fig. 22).

A series of sulfur analogues of **50** were prepared by Vreeze *et al.*¹²⁶ It was found that a sulfone unit could form hydrogen bonds between the oxygen atoms and the backbone nitrogen of residues Asp567 and Gly619, and sulfur oxidation seemed beneficial for bioactivities. Sulfones compounds **54** and **55**, had IC₅₀ values of 1.9 and 3.7 nM, respectively, as well as a 5789-fold and a 3243-fold selectivities against HDAC1. In further modification, compound **56**, with a five-membered thiaheterocyclic ring, was also a potent HDAC6 inhibitor. Meanwhile, five membered sulfones compounds display appropriate preliminary ADME/Tox profile (Fig. 23).¹²⁷

Based on the findings of Butler *et al.*, Leonhardt *et al.* designed a set of tetracyclic tetrahydro- β -carboline derivatives.¹²⁸ The additional piperazine-2,5-dione structure was proven to be more potent than the imidazolidine-2,4-dione structure. Lead compound **57**, with IC₅₀ value of 3.73 nM, was a stronger HDAC6 inhibitor than **50** as well as had a selective




Fig. 22 Structures of carboline based HDAC6 inhibitors.

index of >200 against HDAC1, 2, 4, 8 and 10. By combination of the fluorophore of 4 MS and **50**, Zhang *et al.* designed HDAC6 selective inhibitors **58a** and **58b** as small-molecular fluorescent probes.¹²⁹ **58a** displayed satisfying HDAC6 selectivity with the selective index of over 140, 700 and 210 against HDAC1/2/3 and could label MG132-induced aggresome because of its high HDAC6 selectivity. Encouraged by these positive results, Ho *et al.* synthesized a series of fluorescent HDAC6 selective inhibitors with substituents on the naphthalimide skeleton. Compound **59** with the methoxy group at position 4 of naphthalimide exhibited the greatest HDAC6 inhibitory activity (IC₅₀ = 0.1 nM) and HDAC6/1 selectivity (1080-fold). Compound **59** could also increase α -tubulin acetylation in a dose-dependent manner and showed the most effective activity against six cancer cell lines (Fig. 24).¹⁰²

Through virtual screening, Schlimme *et al.* identified compound **60** as a HDAC6 inhibitor with an IC₅₀ of 300 nM.¹³⁰ In order to further improving the potency and selectivity of **60**, this group reported the preparation of thiazole-, oxazole-, and oxadiazole-containing biarylhydroxamic acids.¹³¹ In general, the thiazole- and oxadiazole-containing derivatives were much less potent and selective than the oxazole containing compounds, and the *para*-position substitutions were better for selectivities. The 4-bromophenyl substituted oxazole hydroxamate **61** was the most potent analogues between these series of compounds, with IC₅₀ value of 59 nM. Docking studies revealed that the oxazole interacted with Phe566 and Phe520, which could explain the high selectivity of *para*-substituted phenyl-oxazoles based compounds (Fig. 25).

Blackburn *et al.* screened several hundred hydroxamic acids for inhibitory activity of HDAC6 and identified 4-(amino-methyl)-N-hydroxybenzamide as potent inhibitors of HDAC6 with improved selectivity.¹³² Heterocyclic analogues such as compound **62** (tetrahydroisoquinolines) showed enhanced HDAC6 selectivity, and had an IC₅₀ of 36 nM against HDAC6. In addition, compound **62** showed negligible inhibition against




Fig. 23 Structures of carboline based HDAC6 inhibitors.






Fig. 24 Structures of carboline based HDAC6 inhibitors.

matrix metalloproteases such as MMPs 2, 9, and 4 (>100 μ M). In further modifications, this group designed three additional series based on 1,2,3,4-tetrahydropyrrolo[1,2-*a*]pyrazine, 4,5,6,7-tetrahydropyrazolopyrazine and 5,6,7,8-tetrahydro-imidazo[1,2-*a*]pyrazines.¹³³ And 63 was the most potent HDAC6 inhibitors in these series of compounds, with IC_{50} value of 33 nM, almost 100-fold selectivity *versus* HDAC8. Homology modeling revealed that fused ring spacer was more effectively occupied the channel of HDAC6, and the hydrophobic capping group interacted with the protein surface (Fig. 26).

Based on the homology model, Bergman *et al.* found that the entrance to the binding site was wider and shallower for HDAC6 than HDAC1, then a series of compounds with the introduction of certain branched-elements to the linker were synthesized.¹³⁴ Structure-activity relationship studies exhibited that compounds bearing a branched linker group resulted in the increased potency and selectivity for HDAC6. The *n*-butyl-containing compound 64 displayed nanomolar inhibitory potency against HDAC6 and indicated excellent selectivity over HDAC1 (600-fold). The same group further reported SAR studies in a series of analogues based on the scaffold of compound 64.¹³⁵ The new compound 65, bearing added indazole ring, exhibited improved potency against HDAC6 (IC_{50} = 1.6 nM) and retained selectivity (450-fold) over HDAC1. Docking simulations revealed that one of the nitrogen atoms in the indazole ring engage in hydrogen bonding interactions with the carbonyl group of Ala641, which may be the reason for the improving HDAC6 activity and selectivity. The *in vivo* studies demonstrated that this compound possessed improving capability to inhibit tumor growth in melanoma models through regulating inflammatory and immune responses (Fig. 27).




Fig. 25 Structures of thiazole and oxazole based HDAC6 inhibitors.




Fig. 26 Structures of novel HDAC6 inhibitors.




Fig. 27 Structures of branched linker based HDAC6 inhibitors.

Lee *et al.* found 66 (HPOB) was a HDAC6 selective inhibitor, with an IC_{50} value of 52 nM against HDAC6, almost 50-fold selectivity over HDAC1. 66 enhanced Etoposide, Doxorubicin, or SAHA-induced transformed cell death, which indicated that 66 had advantage in combination therapy to enhance the potency of antitumor drugs.¹³⁶ In further study, Lee *et al.* described a new selective HDAC6 inhibitor 67 (HPB), with an IC_{50} value of 31 nM, almost 15 to 400-fold more potent than other HDACs.¹³⁷ 67 selectively induced accumulation of acetylated α -tubulin and other substrates of HDAC6. 67 inhibited cell growth but did not influence cell death of normal and transformed cells. However, HPB enhanced transformed cell death caused by the anticancer drugs Paclitaxel or SAHA (Fig. 28).

Diedrich *et al.* designed a series of selective HDAC6 inhibitors utilizing peptoid-based branched cap groups.¹³⁸ The most potent HDAC6 inhibitor 68 (IC_{50} = 1.59 nM) exhibited selectivity index of 46 289 against HDAC4 and 126 against HDAC2. Especially, compound 68 displayed remarkable chemosensitizing properties and completely resensitized Cal27 CisR cell line towards cisplatin. Porter *et al.* reported that 69 (Bavarostat) exhibited more than 16 000-fold selectivity in comparison with HDAC1-3.¹³⁹ Docking studies revealed that the hybridization of the linker benzylic nitrogen and the steric bulky capping group affected the affinity of hydroxamate-Zn²⁺ coordination which contributed to HDAC6 selectivity (Fig. 29).

Bracher *et al.* reported the preparation of phenothiazines based benzhydroxamic acid HDAC6 inhibitors.¹⁴⁰ They confirmed the beneficial effect of the benzylic linker on potency and selectivity for HDAC6 in these series of inhibitors. The lead compound 70 showed impressive HDAC6 inhibition (IC_{50} = 22 nM) and a selectivity factor (SF) of 231 over HDAC1. The selective inhibition of HDAC6 by analogues of 70 (71 and 72) was also validated in cell culture with western blotting of tubulin *versus* histone acetylation. Docking studies of compound 70 to HDAC6 displayed that the tricyclic ring system can interact with the rim of the binding tunnel. Song *et al.* utilized structure-based virtual screening and provided the novel HDAC6 inhibitor 73. This compound inhibited HDAC6 with an IC_{50} value of 56 nM and




Fig. 28 Structures of branched linker based HDAC6 inhibitors.






Fig. 29 Structures of peptoid-based HDAC6 inhibitors.




Fig. 30 Structures of novel HDAC6 inhibitors.

displayed excellent selectivity for HDAC6 over other HDAC isoforms. At the same time, compound 73 could increase the acetylation of α -tubulin but not histone H3, which also confirmed the selectivity for HDAC6 of this inhibitor (Fig. 30).¹⁴¹

4. Conclusions

The development of the selective HDACis have made great progresses through modifying the cap region and linker, however, the design of selective HDACis remains a great challenge. The high sequence homology between catalytic sites as well as the tendency of HDACs *in vivo* to become functionally active multiprotein aggregates limited the development of iso-type specific HDACis, since inhibitory activity of single HDAC could be different from which in protein complexes. It is noting that the development of X-ray crystallography, molecular modeling studies and computer-aided drug design may provide further contributions to the design of novel selective HDACis.

HDACis are more active in hematological cancers than solid tumors, yet the reason is not clear. In order to overcome this issue, the possible strategy is to design multifunctional or multitarget HDACis synthesized by combining pharmacophores of typical HDACis and other inhibitors. A huge number of multi-targets inhibitors based on HDAC inhibitory activity have now been developed and showed remarkable anti-tumor activity. Numerous multi-target inhibitors have been demonstrated the advantages in enhancing anti-tumor efficacy and reducing side effects. However, the design and synthesis of multi-target compounds still require more exploration due to the multifactorial mechanistic nature of cancer. Therefore, the research of multi-target inhibitors is also another important direction for next generation HDACis.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

We acknowledge the financial support from National Natural Science Foundation of China (No. 81673304 and 81703360), Open Research Project Foundation of Shanghai Key Laboratory of Regulatory Biology (2018LBR03), the Natural Science Foundation of Shandong Province (No. ZR2016HB43), the Young Taishan Scholars Program (tsqn20161037), and the Shandong Talents Team Cultivation Plan of University Preponderant Discipline (No. 10027).

References

- 1 E. Abdelfatah, Z. Kerner, N. Nanda and N. Ahuja, *Ther. Adv. Gastroenterol.*, 2016, **9**, 560–579.
- 2 M. Haberland, R. L. Montgomery and E. N. Olson, *Nat. Rev. Genet.*, 2009, **10**, 32–42.
- 3 C. Damaskos, I. Tomos, N. Garmpis, A. Karakatsani, D. Dimitroulis, A. Garmpi, E. Spartalis, C. F. Kampolis, E. Tsagkari, A. A. Loukeri, G.-A. Margonis, M. Spartalis, N. Andreatos, D. Schizas, S. Kokkineli, E. A. Antoniou, A. Nonni, G. Tsourouflis, K. Markatos, K. Kontzoglou, A. Kostakis and P. Tomos, *Anticancer Res.*, 2018, **38**, 37–43.
- 4 Y. Zhang, H. Fang, J. Jiao and W. Xu, *Curr. Med. Chem.*, 2008, **15**, 2840–2849.
- 5 Z. Li and W.-G. Zhu, *Int. J. Biol. Sci.*, 2014, **10**, 757–770.
- 6 A. J. Ruthenburg, H. Li, D. J. Patel and C. D. Allis, *Nat. Rev. Mol. Cell Biol.*, 2007, **8**, 983–994.
- 7 S. A. Ganai, M. Ramadoss and V. Mahadevan, *Curr. Neuropharmacol.*, 2016, **14**, 55–71.
- 8 P. Gallinari, S. Di Marco, P. Jones, M. Pallaoro and C. Steinkuhler, *Cell Res.*, 2007, **17**, 195–211.
- 9 A. J. M. de Ruijter, A. H. van Gennip, H. N. Caron, S. Kemp and A. B. P. van Kuilenburg, *Biochem. J.*, 2003, **370**, 737–749.
- 10 I. V. Gregoretti, Y.-M. Lee and H. V. Goodson, *J. Mol. Biol.*, 2004, **338**, 17–31.
- 11 O. Khan and N. B. La Thangue, *Immunol. Cell Biol.*, 2012, **90**, 85–94.
- 12 M. Haberland, A. Johnson, M. H. Mokalled, R. L. Montgomery and E. N. Olson, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 7751–7755.
- 13 C. J. Millard, P. J. Watson, I. Celardo, Y. Gordiyenko, S. M. Cowley, C. V. Robinson, L. Fairall and J. W. R. Schwabe, *Mol Cell.*, 2013, **51**, 57–67.
- 14 B. E. L. Lauffer, R. Mintzer, R. Fong, S. Mukund, C. Tam, I. Zilberleyb, B. Flicke, A. Ritscher, G. Fedorowicz, R. Vallero, D. F. Ortwine, J. Gunzner, Z. Modrusan, L. Neumann, C. M. Koth, P. J. Lupardus, J. S. Kaminker, C. E. Heise and P. Steiner, *J. Biol. Chem.*, 2013, **288**, 26926–26943.
- 15 P. J. Watson, L. Fairall, G. M. Santos and J. W. R. Schwabe, *Nature*, 2012, **481**, 335–340.



16 J. R. Somoza, R. J. Skene, B. A. Katz, C. Mol, J. D. Ho, A. J. Jennings, C. Luong, A. Arvai, J. J. Buggy, E. Chi, J. Tang, B.-C. Sang, E. Verner, R. Wynands, E. M. Leahy, D. R. Dougan, G. Snell, M. Navre, M. W. Knuth, R. V. Swanson, D. E. McRee and L. W. Tari, *Structure*, 2004, **12**, 1325–1334.

17 M. J. Bottomley, P. Lo Surdo, P. Di Giovine, A. Cirillo, R. Scarpelli, F. Ferrigno, P. Jones, P. Neddermann, R. De Francesco, C. Steinkuhler, P. Gallinari and A. Carfi, *J. Biol. Chem.*, 2008, **283**, 26694–26704.

18 A. Schuetz, J. Min, A. Allali-Hassani, M. Schapira, M. Shuen, P. Loppnau, R. Mazitschek, N. P. Kwiatkowski, T. A. Lewis, R. L. Maglathin, T. H. McLean, A. Bochkarev, A. N. Plotnikov, M. Vedadi and C. H. Arrowsmith, *J. Biol. Chem.*, 2008, **283**, 11355–11363.

19 Y. Hai and D. W. Christianson, *Nat. Chem. Biol.*, 2016, **12**, 741–747.

20 H. Dai, A. W. Case, T. V. Riera, T. Considine, J. E. Lee, Y. Hamuro, H. Zhao, Y. Jiang, S. M. Sweitzer, B. Pietrak, B. Schwartz, C. A. Blum, J. S. Disch, R. Caldwell, B. Szczepankiewicz, C. Oalmann, P. Y. Ng, B. H. White, R. Casaubon, R. Narayan, K. Koppetsch, F. Bourbonais, B. Wu, J. Wang, D. Qian, F. Jiang, C. Mao, M. Wang, E. Hu, J. C. Wu, R. B. Perni, G. P. Vlasuk and J. L. Ellis, *Nat. Commun.*, 2015, **6**, 7645.

21 M. S. Finnin, J. R. Donigian and N. P. Pavletich, *Nat. Struct. Biol.*, 2001, **8**, 621–625.

22 L. Jin, W. Wei, Y. Jiang, H. Peng, J. Cai, C. Mao, H. Dai, W. Choy, J. E. Bemis, M. R. Jirousek, J. C. Milne, C. H. Westphal and R. B. Perni, *J. Biol. Chem.*, 2009, **284**, 24394–24405.

23 J. Du, Y. Zhou, X. Su, J. J. Yu, S. Khan, H. Jiang, J. Kim, J. Woo, J. H. Kim, B. H. Choi, B. He, W. Chen, S. Zhang, R. A. Cerione, J. Auwerx, Q. Hao and H. Lin, *Science*, 2011, **334**, 806–809.

24 P. W. Pan, J. L. Feldman, M. K. Devries, A. Dong, A. M. Edwards and J. M. Denu, *J. Biol. Chem.*, 2011, **286**, 14575–14587.

25 A. Priyanka, V. Solanki, R. Parkesh and K. G. Thakur, *Proteins: Struct., Funct., Bioinf.*, 2016, **84**, 1558–1563.

26 X.-J. Yang and E. Seto, *Nat. Rev. Mol. Cell Biol.*, 2008, **9**, 206–218.

27 C. B. Yoo and P. A. Jones, *Nat. Rev. Drug Discovery*, 2006, **5**, 37–50.

28 F. Thaler and C. Mercurio, *ChemMedChem*, 2014, **9**, 523–536.

29 S. A. Denslow and P. A. Wade, *Oncogene*, 2007, **26**, 5433–5438.

30 A. You, J. K. Tong, C. M. Grozinger and S. L. Schreiber, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 1454–1458.

31 M. J. Pazin and J. T. Kadonaga, *Cell*, 1997, **89**, 325–328.

32 Y. D. Wen, V. Perissi, L. M. Staszewski, W. M. Yang, A. Krones, C. K. Glass, M. G. Rosenfeld and E. Seto, *Proc. Natl. Acad. Sci. U. S. A.*, 2000, **97**, 7202–7207.

33 P. Karagianni and J. Wong, *Oncogene*, 2007, **26**, 5439–5449.

34 J. J. Buggy, M. L. Sideris, P. Mak, D. D. Lorimer, B. McIntosh and J. M. Clark, *Biochem. J.*, 2000, **350**(1), 199–205.

35 X. J. Yang and E. Seto, *Oncogene*, 2007, **26**, 5310–5318.

36 X.-J. Yang and S. Gregoire, *Mol. Cell. Biol.*, 2005, **25**, 2873–2884.

37 B. E. Gryder, Q. H. Sodji and A. K. Oyelere, *Future Med. Chem.*, 2012, **4**, 505–524.

38 S. A. Ganai, *Curr. Drug Targets*, 2018, **19**, 593–601.

39 W. Fischle, F. Dequiedt, M. Fillion, M. J. Hendzel, W. Voelter and E. Verdin, *J. Biol. Chem.*, 2001, **276**, 35826–35835.

40 W. Fischle, F. Dequiedt, M. J. Hendzel, M. G. Guenther, M. A. Lazar, W. Voelter and E. Verdin, *Molecular cell*, 2002, **9**, 45–57.

41 M. Stahl, S. D. Gore, N. Vey and T. Prebet, *Expert Opin. Invest. Drugs*, 2016, **25**, 307–317.

42 C. M. Grozinger, C. A. Hassig and S. L. Schreiber, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 4868–4873.

43 M. Kaliszczak, S. Trousil, O. Aberg, M. Perumal, Q. D. Nguyen and E. O. Aboagye, *Br. J. Cancer*, 2013, **108**, 342–350.

44 T. Li, C. Zhang, S. Hassan, X. Liu, F. Song, K. Chen, W. Zhang and J. Yang, *J. Hematol. Oncol.*, 2018, **11**, 111.

45 P. Bose, Y. Dai and S. Grant, *Pharmacol. Ther.*, 2014, **143**, 323–336.

46 A. Grabarska, M. Dmoszynska-Graniczka, E. Nowosadzka and A. Stepulak, *Postepy Hig. Med. Dosw.*, 2013, **67**, 722–735.

47 W. Weichert, A. Roske, V. Gekeler, T. Beckers, C. Stephan, K. Jung, F. R. Fritzsche, S. Niesporek, C. Denkert, M. Dietel and G. Kristiansen, *Br. J. Cancer*, 2008, **98**, 604–610.

48 W. Weichert, A. Roske, V. Gekeler, T. Beckers, M. P. A. Ebert, M. Pross, M. Dietel, C. Denkert and C. Rocken, *Lancet Oncol.*, 2008, **9**, 139–148.

49 A. J. Wilson, D.-S. Byun, N. Popova, L. B. Murray, K. L'Italien, Y. Sowa, D. Arango, A. Velcich, L. H. Augenlicht and J. M. Mariadason, *J. Biol. Chem.*, 2006, **281**, 13548–13558.

50 G. Giannini, W. Cabri, C. Fattorusso and M. Rodriguez, *Future Med. Chem.*, 2012, **4**, 1439–1460.

51 C. Choudhary, C. Kumar, F. Gnad, M. L. Nielsen, M. Rehman, T. C. Walther, J. V. Olsen and M. Mann, *Science*, 2009, **325**, 834–840.

52 P. Marks, R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller and W. K. Kelly, *Nat. Rev. Cancer*, 2001, **1**, 194–202.

53 M. A. Glozak, N. Sengupta, X. Zhang and E. Seto, *Gene*, 2005, **363**, 15–23.

54 A. C. West and R. W. Johnstone, *J. Clin. Invest.*, 2014, **124**, 30–39.

55 R. D. Glick, S. L. Swendeman, D. C. Coffey, R. A. Rifkind, P. A. Marks, V. M. Richon and M. P. La Quaglia, *Cancer Res.*, 1999, **59**, 4392–4399.

56 A. C. West and R. W. Johnstone, *J. Clin. Invest.*, 2014, **124**, 30–39.

57 V. Carafa, M. Miceli, L. Altucci and A. Nebbioso, *Expert Opin. Ther. Pat.*, 2013, **23**, 1–17.

58 J. P. Laubach, J. F. San-Miguel, V. Hungria, J. Hou, P. Moreau, S. Lonial, J. H. Lee, H. Einsele, M. Alsina and P. G. Richardson, *Expert Rev. Hematol.*, 2017, **10**, 229–237.



59 B. Juliandi, M. Abematsu, T. Sanosaka, K. Tsujimura, A. Smith and K. Nakashima, *Neurosci. Res.*, 2012, **72**, 23–31.

60 P. Zhan, Y. Itoh, T. Suzuki and X. Liu, *J. Med. Chem.*, 2015, **58**, 7611–7633.

61 C. Micelli and G. Rastelli, *Drug Discovery Today*, 2015, **20**, 718–735.

62 M. S. Finnin, J. R. Donigian, A. Cohen, V. M. Richon, R. A. Rifkind, P. A. Marks, R. Breslow and N. P. Pavletich, *Nature*, 1999, **401**, 188–193.

63 R. Sangwan, R. Rajan and P. K. Mandal, *Eur. J. Med. Chem.*, 2018, **158**, 620–706.

64 F. F. Wagner, U. M. W. yi, M. C. Lewis and E. B. Holson, *Neurotherapeutics*, 2013, **10**, 589–604.

65 L. Cappellacci, D. R. Perinelli, F. Maggi, M. Grifantini and R. Petrelli, *Curr. Med. Chem.*, 2018, **16**, DOI: 10.2174/092986732566181016163110.

66 T. Eckschlager, J. Plch, M. Stiborova and J. Hrabetá, *Int. J. Mol. Sci.*, 2017, **18**, 1414.

67 B. S. Mann, J. R. Johnson, M. H. Cohen, R. Justice and R. Pazdur, *Oncologist*, 2007, **12**, 1247–1252.

68 C. Grant, F. Rahman, R. Piekarz, C. Peer, R. Frye, R. W. Robey, E. R. Gardner, W. D. Figg and S. E. Bates, *Expert Rev. Anticancer Ther.*, 2011, **11**, 1622.

69 W. Chien, D. H. Lee, Y. Zheng, P. Wuensche, R. Alvarez, D. L. Wen, A. M. Aribi, S. M. Thean, N. B. Doan, J. W. Said and H. P. Koeffler, *Mol. Carcinog.*, 2014, **53**, 722–735.

70 D. Sivaraj, M. M. Green and C. Gasparetto, *Future Oncol.*, 2017, **13**, 477–488.

71 C. H. Arrowsmith, C. Bountra, P. V. Fish, K. Lee and M. Schapira, *Nat. Rev. Drug Discovery*, 2012, **11**, 384–400.

72 K. J. Falkenberg and R. W. Johnstone, *Nat. Rev. Drug Discovery*, 2014, **13**, 673–691.

73 D. Liao, *Drug Discovery Today: Technol.*, 2015, **18**, 24–28.

74 P. Chang, M. Weykamp, I. S. Dennahy, A. M. Williams, U. F. Bhatti, B. Liu, V. C. Nikolian, Y. Li and H. B. Alam, *J. Trauma Acute Care Surg.*, 2018, **84**, 795–801.

75 C. Micelli and G. Rastelli, *Drug Discovery Today*, 2015, **20**, 718–735.

76 L. Zhang, Y. Han, Q. Jiang, C. Wang, X. Chen, X. Li, F. Xu, Y. Jiang, Q. Wang and W. Xu, *Med. Res. Rev.*, 2015, **35**, 63–84.

77 F. Thaler and C. Mercurio, *ChemMedChem*, 2014, **9**, 523–526.

78 T. Y. Taha, S. M. Aboukhatwa, R. C. Knopp, N. Ikegaki, H. Abdelkarim, J. Neerasa, Y. Lu, R. Neelarapu, T. W. Hanigan, G. R. J. Thatcher and P. A. Petukhov, *ACS Med. Chem. Lett.*, 2017, **8**, 824–829.

79 A. R. Maolanon, A. S. Madsen and C. A. Olsen, *Cell Chem. Biol.*, 2016, **23**, 759–768.

80 M. Marek, T. B. Shaik, T. Heimburg, A. Chakrabarti, J. Lancelot, E. Ramos-Morales, C. Da Veiga, D. Kalinin, J. Melesina, D. Robaa, K. Schmidtkunz, T. Suzuki, R. Holl, E. Ennifar, R. J. Pierce, M. Jung, W. Sippl and C. Romier, *J. Med. Chem.*, 2018, **61**, 10000–10016.

81 T. Beckers, C. Burkhardt, H. Wieland, P. Gimmlich, T. Ciossek, T. Maier and K. Sanders, *Int. J. Cancer*, 2007, **121**, 1138–1148.

82 N. Khan, M. Jeffers, S. Kumar, C. Hackett, F. Boldog, N. Khramtsov, X. Qian, E. Mills, S. C. Berghs, N. Carey, P. W. Finn, L. S. Collins, A. Tumber, J. W. Ritchie, P. B. Jensen, H. S. Lichenstein and M. Sehested, *Biochem. J.*, 2008, **409**, 581–589.

83 P. Siliphavanh, P. Harrington, D. J. Witter, K. Otte, P. Tempest, S. Kattar, A. M. Kral, J. C. Fleming, S. V. Deshmukh, A. Harsch, P. J. Sechrist and T. A. Miller, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 4619–4624.

84 D. J. Witter, P. Harrington, K. J. Wilson, M. Chenard, J. C. Fleming, B. Haines, A. M. Kral, J. P. Sechrist and T. A. Miller, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 726–731.

85 O. M. Moradei, T. C. Mallais, S. Frechette, I. Paquin, P. E. Tessier, S. M. Leit, M. Fournel, C. Bonfils, M.-C. Trachy-Bourget, J. Liu, T. P. Yan, A.-H. Lu, J. Rahil, J. Wang, S. Lefebvre, Z. Li, A. F. Vaisburg and J. M. Besterman, *J. Med. Chem.*, 2007, **50**, 5543–5546.

86 T. Suzuki, Y. Kasuya, Y. Itoh, Y. Ota, P. Zhan, K. Asamitsu, H. Nakagawa, T. Okamoto and N. Miyata, *PLoS One*, 2013, **8**, e68669.

87 C. M. Marson, C. J. Matthews, S. J. Atkinson, N. Lamadema and N. S. Thomas, *J. Med. Chem.*, 2015, **58**, 6803–6818.

88 H.-Y. Hsieh, H.-C. Chuang, F.-H. Shen, K. Detroja, L.-W. Hsin and C.-S. Chen, *Eur. J. Med. Chem.*, 2017, **140**, 42–51.

89 I. Van den Wyngaert, W. de Vries, A. Kremer, J. Neefs, P. Verhasselt, W. H. Luyten and S. U. Kass, *FEBS Lett.*, 2000, **478**, 77–83.

90 A. Chakrabarti, J. Melesina, F. R. Kolbinger, I. Oehme, J. Senger, O. Witt, W. Sippl and M. Jung, *Future Med. Chem.*, 2016, **8**, 1609–1634.

91 Y. Zhang, J. Feng, C. Liu, L. Zhang, J. Jiao, H. Fang, L. Su, X. Zhang, J. Zhang, M. Li, B. Wang and W. Xu, *Bioorg. Med. Chem.*, 2010, **18**, 1761–1772.

92 Y. Zhang, J. Feng, Y. Jia, X. Wang, L. Zhang, C. Liu, H. Fang and W. Xu, *J. Med. Chem.*, 2011, **54**, 2823–2838.

93 Y. Zhang, J. Feng, Y. Jia, Y. Xu, C. Liu, H. Fang and W. Xu, *Eur. J. Med. Chem.*, 2011, **46**, 5387–5397.

94 C. Zhao, J. Zang, Q. g. Ding, E. S. Inks, W. Xu, C. J. Chou and Y. Zhang, *Eur. J. Med. Chem.*, 2018, **150**, 282–291.

95 R. Neelarapu, D. L. Holzle, S. Velaparthi, H. Bai, M. Brunsteiner, S. Y. Blond and P. A. Petukhov, *J. Med. Chem.*, 2011, **54**, 4350–4364.

96 W. Tang, T. Luo, E. F. Greenberg, J. E. Bradner and S. L. Schreiber, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 2601–2605.

97 T. Suzuki, Y. Ota, M. Ri, M. Bando, A. Gotoh, Y. Itoh, H. Tsumoto, P. R. Tatum, T. Mizukami, H. Nakagawa, S. Iida, R. Ueda, K. Shirahige and N. Miyata, *J. Med. Chem.*, 2012, **55**, 9562–9575.

98 T. Suzuki, N. Muto, M. Bando, Y. Itoh, A. Masaki, M. Ri, Y. Ota, H. Nakagawa, S. Iida, K. Shirahige and N. Miyata, *ChemMedChem*, 2014, **9**, 657–664.

99 O. J. Ingham, R. M. Paranal, W. B. Smith, R. A. Escobar, H. Yueh, T. Snyder, J. A. Porco Jr, J. E. Bradner and A. B. Beeler, *ACS Med. Chem. Lett.*, 2016, **7**, 929–932.

100 W.-J. Huang, Y.-C. Wang, S.-W. Chao, C.-Y. Yang, L.-C. Chen, M.-H. Lin, W.-C. Hou, M.-Y. Chen, T.-L. Lee,



P. Yang and C.-I. Chang, *ChemMedChem*, 2012, **7**, 1815–1824.

101 T. Y. Taha, S. M. Aboukhatwa, R. C. Knopp, N. Ikegaki, H. Abdelkarim, J. Neerasa, Y. Lu, R. Neelarapu, T. W. Hanigan, G. R. J. Thatcher and P. A. Petukhov, *ACS Med. Chem. Lett.*, 2017, **8**, 824–829.

102 Y.-H. Ho, K.-J. Wang, P.-Y. Hung, Y.-S. Cheng, J.-R. Liu, S.-T. Fung, P.-H. Liang, J.-W. Chern and C.-W. Yu, *Org. Biomol. Chem.*, 2018, **16**, 7820–7832.

103 J. Asthana, S. Kapoor, R. Mohan and D. Panda, *J. Biol. Chem.*, 2013, **288**, 22516–22526.

104 Y. Liu, L. Li and J. Min, *Nat. Chem. Biol.*, 2016, **12**, 660–661.

105 Y. Liu, L. Li and J. Min, *Nat. Chem. Biol.*, 2016, **12**, 885.

106 G. W. G. Luxton and G. G. Gundersen, *Dev. Cell*, 2007, **13**, 161–162.

107 G. I. Aldana-Masangkay and K. M. Sakamoto, *J. Biomed. Biotechnol.*, 2011, **2011**, 875824.

108 X. X. Wang, R. Z. Wan and Z. P. Liu, *Eur. J. Med. Chem.*, 2018, **143**, 1406–1418.

109 T. Liang and H. Fang, *Curr. Top. Med. Chem.*, 2018, **18**, 2429–2447.

110 S. J. Haggarty, K. M. Koeller, J. C. Wong, R. A. Butcher and S. L. Schreiber, *Chem. Biol.*, 2003, **10**, 383–396.

111 G. Estiu, E. Greenberg, C. B. Harrison, N. P. Kwiatkowski, R. Mazitschek, J. E. Bradner and O. Wiest, *J. Med. Chem.*, 2008, **51**, 2898–2906.

112 L. Santo, T. Hidemitsu, A. L. Kung, J.-C. Tseng, D. Tamang, M. Yang, M. Jarpe, J. H. van Duzer, R. Mazitschek, W. C. Ogier, D. Cirstea, S. Rodig, H. Eda, T. Scullen, M. Canavese, J. Bradner, K. C. Anderson, S. S. Jones and N. Raje, *Blood*, 2012, **119**, 2579–2589.

113 P. Huang, I. Almeciga-Pinto, M. Jarpe, J. H. van Duzer, R. Mazitschek, M. Yang, S. S. Jones and S. N. Quayle, *Oncotarget*, 2017, **8**, 2694–2707.

114 A. P. Kozikowski, Y. Chen, A. M. Gaysin, D. N. Savoy, D. D. Billadeau and K. H. Kim, *ChemMedChem*, 2008, **3**, 487–501.

115 Y. Chen, M. Lopez-Sanchez, D. N. Savoy, D. D. Billadeau, G. S. Dow and A. P. Kozikowski, *J. Med. Chem.*, 2008, **51**, 3437–3448.

116 A. P. Kozikowski, S. Tapadar, D. N. Luchini, K. H. Kim and D. D. Billadeau, *J. Med. Chem.*, 2008, **51**, 4370–4373.

117 Z. Yang, T. Wang, F. Wang, T. Niu, Z. Liu, X. Chen, C. Long, M. Tang, D. Cao, X. Wang, W. Xiang, Y. Yi, L. Ma, J. You and L. Chen, *J. Med. Chem.*, 2016, **59**, 1455–1470.

118 W. Duan, J. Li, E. S. Inks, C. J. Chou, Y. Jia, X. Chu, X. Li, W. Xu and Y. Zhang, *J. Med. Chem.*, 2015, **58**, 4325–4338.

119 J. Yang, G. Cheng, Q. Xu, S. Luan, S. Wang, D. Liu and L. Zhao, *Bioorg. Med. Chem.*, 2018, **26**, 1418–1425.

120 E. G. Yang, N. Mustafa, E. C. Tan, A. Poulsen, P. M. Ramanujulu, W. J. Chng, J. J. Y. Yen and B. W. Dymock, *J. Med. Chem.*, 2016, **59**, 8233–8262.

121 L. Yao, N. Mustafa, E. C. Tan, A. Poulsen, P. Singh, D.-T. Minh-Dao, J. X. T. Lee, P. M. Ramanujulu, W. J. Chng, J. J. Y. Yen, S. Ohlson and B. W. Dymock, *J. Med. Chem.*, 2017, **60**, 8336–8357.

122 L. Yao, P. M. Ramanujulu, A. Poulsen, S. Ohlson and B. W. Dymock, *Bioorg. Med. Chem. Lett.*, 2018, **28**, 2636–2640.

123 K. V. Butler, J. Kalin, C. Brochier, G. Vistoli, B. Langley and A. P. Kozikowski, *J. Am. Chem. Soc.*, 2010, **132**, 10842–10846.

124 J. H. Kalin, K. V. Butler, T. Akimova, W. W. Hancock and A. P. Kozikowski, *J. Med. Chem.*, 2012, **55**, 639–651.

125 S. Shen, V. Benoy, J. K. Bergman, J. H. Kalin, M. Frojuello, G. Vistoli, W. Haeck, L. Van Den Bosch and A. P. Kozikowski, *ACS Chem. Neurosci.*, 2016, **7**, 240–258.

126 R. De Vreese, T. Verhaeghe, T. Desmet and M. D'Hooghe, *Chem. Commun.*, 2013, **49**, 3775–3777.

127 R. De Vreese, Y. Depetter, T. Verhaeghe, T. Desmet, V. Benoy, W. Haeck, L. Van Den Bosch and M. D'Hooghe, *Org. Biomol. Chem.*, 2016, **14**, 2537–2549.

128 M. Leonhardt, A. Sellmer, O. H. Kraemer, S. Dove, S. Elz, B. Kraus, M. Beyer and S. Mahboobi, *Eur. J. Med. Chem.*, 2018, **152**, 329–357.

129 Y. Zhang, J. Yan and T.-P. Yao, *Eur. J. Med. Chem.*, 2017, **141**, 596–602.

130 S. Schlimme, A.-T. Hauser, V. Carafa, R. Heinke, S. Kannan, D. A. Stolfa, S. Cellamare, A. Carotti, L. Altucci, M. Jung and W. Sippl, *ChemMedChem*, 2011, **6**, 1193–1198.

131 J. Senger, J. Melesina, M. Marek, C. Romier, I. Oehme, O. Witt, W. Sippl and M. Jung, *J. Med. Chem.*, 2016, **59**, 1545–1555.

132 C. Blackburn, C. Barrett, J. Chin, K. Garcia, K. Gigstad, A. Gould, J. Gutierrez, S. Harrison, K. Hoar, C. Lynch, R. S. Rowland, C. Tsu, J. Ringeling and H. Xu, *J. Med. Chem.*, 2013, **56**, 7201–7211.

133 C. Blackburn, C. Barrett, M. Brunson, J. Chin, D. England, K. Garcia, K. Gigstad, A. Gould, J. Gutierrez, K. Hoar, R. S. Rowland, C. Tsu, J. Ringeling, K. Wager and H. Xu, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 5450–5454.

134 J. A. Bergman, K. Woan, P. Perez-Villarroel, A. Villagra, E. M. Sotomayor and A. P. Kozikowski, *J. Med. Chem.*, 2012, **55**, 9891–9899.

135 M. T. Tavares, S. Shen, T. Knox, M. Hadley, Z. Kutil, C. Barinka, A. Villagra and A. P. Kozikowski, *ACS Med. Chem. Lett.*, 2017, **8**, 1031–1036.

136 J.-H. Lee, A. Mahendran, Y. Yao, L. Ngo, G. Venta-Perez, M. L. Choy, N. Kim, W.-S. Ham, R. Breslow and P. A. Marks, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 15704–15709.

137 J.-H. Lee, Y. Yao, A. Mahendran, N. Lang, G. Venta-Perez, M. L. Choy, R. Breslow and P. A. Marks, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, E5899.

138 D. Diedrich, A. Hamacher, C. G. W. Gertzen, L. A. A. Avelar, G. J. Reiss, T. Kurz, H. Gohlke, M. U. Kassack and F. K. Hansen, *Chem. Commun.*, 2016, **52**, 3219–3222.

139 N. J. Porter, J. D. Osko, D. Diedrich, T. Kurz, J. M. Hooker, F. K. Hansen and D. W. Christianson, *J. Med. Chem.*, 2018, **61**, 8054–8060.

140 K. Voegerl, N. Ong, J. Senger, D. Herp, K. Schmidtkunz, M. Marek, M. Mueller, K. Bartel, T. B. Shaik, N. J. Porter, D. Robaa, D. W. Christianson, C. Romier, W. Sippl, M. Jung and F. Bracher, *J. Med. Chem.*, 2019, **62**, 1138–1166.

141 Y. Song, J. Lim and Y. H. Seo, *Eur. J. Med. Chem.*, 2019, **164**, 263–272.

